RACURA ONCOLOGY
Who is RACURA ONCOLOGY?
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of...See more
Industry & Specialities
Pharmaceuticals
Manufacturing
Countries of Operation
Australia
Headquarters:
Australia
Company Type:
MNC / Large Enterprise
Company size:
11-50 Employees
Year Founded:
2016 (10 years)
Address:
1 MACQUARIE PLACE; LEVEL 36; SYDNEY, NSW 2000, AU
Employees by Department
- Operations (1)
- The Rest (8)
- Total (9)
Key Decision Makers
Sophia Moscovis Mrsn
Vice President Operations & Strategy
Michael Kelso
Vice President of Research
Simon Fisher
Vice President, Medical
Michelle Huh
Clinical Trials Manager
Employees by Seniority
C-level
1employees
Senior
2employees
Non-managers
2employees
Financials
LOW
spending power
Funding Status
Publicly listed on stock exchange
Associated Legal Entities
0 entities
Discover More Companies
Lookalike companies
Featured Lists
- SMEs in Singapore
- MNCs / Large Enterprises in Singapore
Frequently Asked Questions (FAQ)
- How long has RACURA ONCOLOGY been operating for?
- What is the funding status of RACURA ONCOLOGY?
- Where is RACURA ONCOLOGY's headquarter?
- What RACURA ONCOLOGY's spending power?
- Does RACURA ONCOLOGY have a presence in the domain it operates in?